Both authors contributed equally. Conflicts of Interest: U.P. is a consultant of Dynavax/Rheinbiotech for scientific aspects of HBV vaccine development. S.K., T.B., C.D. and M.S. declare no conflict of interest.
Design of therapeutic vaccines: hepatitis B as an example
Article first published online: 29 SEP 2011
© 2011 The Authors. Microbial Biotechnology © 2011 Society for Applied Microbiology and Blackwell Publishing Ltd
Special Issue: Microbial Vaccines and Immunomodulators. Guest Editors: Carlos A. Guzman, Ennio De Gregorio, Jan ter Meulen, and Martin Friede
Volume 5, Issue 2, pages 270–282, March 2012
How to Cite
Kutscher, S., Bauer, T., Dembek, C., Sprinzl, M. and Protzer, U. (2012), Design of therapeutic vaccines: hepatitis B as an example. Microbial Biotechnology, 5: 270–282. doi: 10.1111/j.1751-7915.2011.00303.x
- Issue published online: 20 FEB 2012
- Article first published online: 29 SEP 2011
- Received 7 July, 2011; revised 22 August, 2011; accepted 22 August, 2011.
This article has been cited by:
- 1Mannosylated and lipid A-incorporating cationic liposomes constituting microneedle arrays as an effective oral mucosal HBV vaccine applicable in the controlled temperature chain, Colloids and Surfaces B: Biointerfaces, 2015, 126, 520, , , , , ,
- 2An autophagosome-based therapeutic vaccine for HBV infection: a preclinical evaluation, Journal of Translational Medicine, 2014, 12, 1, 361, , , , , , , , , ,
- 3Strategies to eliminate HBV infection, Future Virology, 2014, 9, 6, 565, ,
- 4Complete Definition of Immunological Correlates of Protection and Clearance of Hepatitis C Virus Infection: A Relevant Pending Task for Vaccine Development, International Reviews of Immunology, 2012, 31, 3, 223, ,